BioCorRx Inc. (BICX)

[HOCO1]

FDA is expediting the development of new addiction treatment options

Indivior just got their injectable opioid treatment FDA fast track approved. This is just the beginning. There are three current solutions. They are not in competition. They suit different patient situations or conditions. There are articles out there written about this. They are Methadone, buprenorphine (Indivior's compound), Naltrexone (as you know - BioCorRx's compound). This is positive.

FDA Commissioner Scott Gottlieb said that Sublocade was “part of our ongoing work in supporting the treatment of those suffering from addiction to opioids.” The approval of the long-acting buprenorphine was in line with the FDA’s plans to “issue guidance to expedite the development of new addiction treatment options,” he said a statement.

https://www.statnews.com/2017/11/30/fda-indivior-opioid-treatment/